Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
WILMINGTON, Del. & BOSTON--(BUSINESS WIRE)---- $INCY #ASCO21--Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory D
OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses
07:30pm, Tuesday, 01'st Jun 2021
INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet red
Incyte: Slowly Moving Along
01:16pm, Monday, 24'th May 2021
Incyte has seen some product approvals in 2020, starting to make an initial dent to drive diversification going forward. I like the potential of the company over the long haul, as diversification effo
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO21--Positive Analysis from Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at ASCO 2021
Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
05:14pm, Wednesday, 19'th May 2021
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO21--Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
Incyte (INCY) Announces Positive Results From Vitiligo Study
06:02pm, Tuesday, 18'th May 2021
Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.
Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions
12:36pm, Monday, 17'th May 2021
Incyte Corporation (NASDAQ: INCY) has announced positive topline results from its pivotal Phase 3 TRuE-V trial program evaluating ruxolitinib cream in adolescent and adult patients (age ≥12 year
Data From Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
04:18pm, Wednesday, 12'th May 2021
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2021--Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
Crescendo Biologics Further Strengthens Leadership Team With Appointment of Dr Michael Booth as Chief Financial Officer
03:00am, Monday, 10'th May 2021
CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appoint
Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi
03:02pm, Tuesday, 04'th May 2021
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q1 2021 Results - Earnings Call Transcript
02:41pm, Tuesday, 04'th May 2021
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q1 2021 Results - Earnings Call Transcript
Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance
12:17pm, Tuesday, 04'th May 2021
Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of $659.2 million. Overall product and r
Is a Surprise Coming for Incyte (INCY) This Earnings Season?
09:01am, Monday, 03'rd May 2021
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SID2021--Incyte Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology Virtual Meeting 2021
Incyte to Present at Upcoming Investor Conference
08:00am, Tuesday, 27'th Apr 2021
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conference
